CTRI/2020/12/029734
Completed
未知
A Prospective, pilot, randomized, single-center, clinical study to evaluate theeffectiveness and safety of Zolpidem Tartrate combined with cognitive behavioral therapyverses cognitive behavioral therapy alone in patients with insomnia associated with comorbidanxiety.
Dr Mahesh Gowda0 sites50 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: F411- Generalized anxiety disorder
- Sponsor
- Dr Mahesh Gowda
- Enrollment
- 50
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male and female patients above 18 years of age.
- •2\. Patients with HAM A score of at least 18\) with known history of insomnia (ISI \=7\) not on pharmacotherapy
- •3\. Patients on psychotropics, after a washout period equivalent to four half\-lives of the drug 4\. The patient has read the informed consent form, has understood the relevant aspects of the clinical study, and grants his/her authorization to participate by signing the informed consent form before the inclusion in the clinical study and the performance of any procedure
- •5\. Patients willing to fill patient diaries, have good compliance, and willing to comply with the study procedure and requirements
- •6\. Patients with no mental disease and are not using psychoactive medications
- •7\. Both male and female (of childbearing potential) patients willing to use appropriate method of contraception as per investigator’s discretion, throughout the study. Female of childbearing potential must have a negative pregnancy test and be non\-lactating at screening visit.
Exclusion Criteria
- •1\. Patients with sleep disorder such as narcolepsy, presence or suspicion of periodic leg movement or restless leg syndrome or obstructive sleep apnea syndrome or with severe, life\-threatening chronic sleep disorders, hepatic failure, thyroid dysfunction, cardiovascular diseases, myasthenia gravis, respiratory insufficiency, anaphylaxis and angioedema
- •2\. Patients with severe psychiatric disorder or a history of major psychiatric disorder (e.g. depression, autism, suicide attempt, bipolar disorder, schizophrenia etc.) or psychomotor impairment
- •3\. Patients taking sleep medications, psychotherapy or acupuncture for insomnia within a month prior to enrolment into the study
- •4\. Patients with a history of drug addiction, drug or alcohol abuse or likely to concomitantly consume alcoholic beverages more than 3 times/week
- •5\. Patients with a progressive medical illness (e.g., cancer, dementia) directly related to the onset and course of insomnia
- •6\. Patients who take medications known to alter sleep (e.g., Alpha\-blockers, Betablockers, Corticosteroids, SSRI antidepressants, ACE inhibitors, ARBs Cholinesterase inhibitors, Histamine 1 antagonists, Glucosamine/chondroitin, and Statins)
- •7\. Patients with an evidence of sleep\-disordered breathing or sleep\-related movement disorder
- •8\. Patients with nightshift work or irregular sleep schedule
- •9\. Patients participated in any investigational drug trial within 4 weeks prior to enrolment into the study
- •10\. Patients with hypersensitivity to zolpidem tartrate or any of the inactive ingredients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A single-centre study to check the visual performance and reduction in farsightedness in children with use of DIMSHYP spectacle lensesHealth Condition 1: H533- Other and unspecified disorders ofbinocular visionCTRI/2024/08/072260Dr. Agarwal’s Eye Hospital Limited
Recruiting
Not Applicable
Applying a high frequency stimulator intended for shoulder pain patientsKCT0002545Chonbuk National University Hospital38
Active, not recruiting
Phase 1
Study to assess the safety of Bilastine treatment regarding psychomotor performance using a virtual reality tool (AULA®), in 9 to 11 years old children with allergic rhinitis and/or urticaria.EUCTR2018-003940-21-ESFAES FARMA, S.A.30
Not yet recruiting
Not Applicable
A single-center, prospective, randomized, exploratory study to investigate the influence of ARNI (angiotensin receptor neprilysin inhibitor) in patients with hemodialysis and heart failure: SPREAD trialChronic heart failureJPRN-UMIN000050122Masuko Memorial Hospital374
Recruiting
Not Applicable
Prospective, randomized controlled, single center study evaluating additional respiration therapy with a PEP trainer to prevent pneumonia in patients with higher neutropenic risk under chemotherapeutic treatment of an acute myeloic leukemiaC92J18Myeloid leukaemiaPneumonia, organism unspecifiedDRKS00019842Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin100